BACKGROUND: Recent studies have shown that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for unresectable @entity157 ( @entity157 ) may offer a survival advantage compared to monotherapy. PURPOSE: To study the effectiveness of combination therapy with RFA and TACE compared to that of TACE alone in a Scandinavian tertiary liver @entity5 center. MATERIAL AND METHODS: A retrospective study of the @entity1 treated with combination therapy vis-  -vis TACE alone from June 2007 to November 2012 was performed. Eighteen @entity1 were treated with a combination of RFA and TACE with an interval of 1-4 days between the treatments. For comparison, a group of 18 @entity1 treated with TACE as monotherapy in the same time period was matched with the combination group by demographic data, @entity5 characteristics, biochemical and clinical parameters, and performance status (PS). RESULTS: Each group consisted of 14 @entity1 with @entity82 and four without. There were no significant differences between the groups regarding age, gender, @entity5 characteristics, causes of @entity82 , levels of @entity648 , @entity1011 , prothrombin time, @entity1 Pugh score, or @entity347 ( @entity347 ) performance status. The median survival of @entity1 in the RFA   +   TACE combination group was 586 days compared to 296 days in the control group. The difference was not statistically significant (P   =   0.26). However, when we stratified the data for @entity82 and @entity347 performance status, @entity1 in the combination group had significantly better survival (P   =   0.024). CONCLUSION: Combination therapy with RFA and TACE for unresectable @entity157 , compared to TACE alone, may offer a survival benefit for a selected group of @entity1 with @entity157 .

Combination of radiofrequency ablation with transarterial chemoembolization for treatment of XXXX : experience from a Danish tertiary liver center.

@entity1 :: ('9606', 'Species') :: ['Child', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity347 :: ('MESH:D019965', 'Disease') :: ['World Health Organization', 'WHO']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
